BioSpace News Archive

Opthea to Present at the FLORetina 2022 Congress

Opthea Limited announce a podium talk will be presented at the annual FLORetina congress, taking place in Rome, Italy from December 8-11, 2022.

December 6, 2022
·
2 min read
Biotech Beach

Healis Therapeutics selected to present at 2023 Biotech Showcase in San Francisco

Healis Therapeutics is pleased to announce that it has been competitively selected to present at the Biotech Showcase taking place January 9-11, 2023 in San Francisco.

December 6, 2022
·
1 min read
Biotech Beach

Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress

Poseida Therapeutics, Inc. today announced it will present early clinical results from its Phase 1 clinical trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) 2022 Annual Congress, taking place in Geneva, Switzerland and online from December 7-9, 2022.

December 6, 2022
·
8 min read
Policy

MTTI Receives Chinese Patent for EVATHERA Technology

Molecular Targeting Technologies, Inc. announces the issuance of Chinese Patent CN109153641B covering MTTI’s lead radiotherapeutic product, EBTATE™ and others in its EvaThera™ platform.

December 6, 2022
·
2 min read
CMS (867.HK) Joins Hand with Incyte on Ruxolitinib Cream, Brings 1st Repigmentation Drug for Vitiligo Patient

China Medical System Holdings Limited (CMS, 867.HK) acquired another blockbuster innovative product in dermatology filed.

December 6, 2022
·
7 min read
Drug Development

Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease

Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced positive, initial clinical data from the first two patients with sickle cell disease (SCD) treated with EDIT-301 in the Phase 1/2 RUBY trial.

December 6, 2022
·
7 min read
Business

Caris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy

Caris Life Sciences and Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced a strategic collaboration to advance clinical development of Hummingbird Bioscience’s anti-HER3 therapy, HMBD-001.

December 6, 2022
·
6 min read
Business

Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD).

December 6, 2022
·
10 min read
Business

EndoGastric Solutions, Inc.® Announces CEO Transition and $18M Financing to Expand Commercialization

EndoGastric Solutions, Inc.® (EGS) announced that Darin Hammers had been appointed to be President and Chief Executive Officer of the Company and a member of the Board of Directors.

December 6, 2022
·
3 min read
Business

Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab

Equillium grants Ono an option to purchase rights to itolizumab.

December 6, 2022
·
12 min read